Ublituximab: Difference between revisions
Content deleted Content added
Updating {{infobox_drug}} (changes to verified fields - updated 'ChemSpiderID_Ref') per Chem/infobox_drug validation (report errors or bugs) |
update |
||
Line 44: | Line 44: | ||
'''Ublituximab''' is an immunomodulator. It binds to [[CD20]].<ref>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf | format=PDF}}</ref> |
'''Ublituximab''' is an immunomodulator. It binds to [[CD20]].<ref>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf | format=PDF}}</ref> |
||
It is currently in [[phase 2]] trials for [[multiple sclerosis]].<ref>https://clinicaltrials.gov/ct2/show/NCT02738775</ref> |
|||
== References == |
== References == |
Revision as of 20:38, 13 December 2016
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | CD20 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
(what is this?) (verify) |
Ublituximab is an immunomodulator. It binds to CD20.[1]
It is currently in phase 2 trials for multiple sclerosis.[2]
References
- ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
- ^ https://clinicaltrials.gov/ct2/show/NCT02738775